PL2315591T3 - Nowe inhibitory pirolowe reduktazy s-nitrozoglutationu jako środki terapeutyczne - Google Patents
Nowe inhibitory pirolowe reduktazy s-nitrozoglutationu jako środki terapeutyczneInfo
- Publication number
- PL2315591T3 PL2315591T3 PL09807383.6T PL09807383T PL2315591T3 PL 2315591 T3 PL2315591 T3 PL 2315591T3 PL 09807383 T PL09807383 T PL 09807383T PL 2315591 T3 PL2315591 T3 PL 2315591T3
- Authority
- PL
- Poland
- Prior art keywords
- therapeutic agents
- nitrosoglutathione reductase
- novel pyrrole
- pyrrole inhibitors
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/323—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8931308P | 2008-08-15 | 2008-08-15 | |
US11698208P | 2008-11-21 | 2008-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2315591T3 true PL2315591T3 (pl) | 2016-09-30 |
Family
ID=41669340
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL09807378T PL2318006T3 (pl) | 2008-08-15 | 2009-08-14 | Nowe inhibitory pirolowe reduktazy S-nitrozoglutationu jako środki terapeutyczne |
PL09807383.6T PL2315591T3 (pl) | 2008-08-15 | 2009-08-14 | Nowe inhibitory pirolowe reduktazy s-nitrozoglutationu jako środki terapeutyczne |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL09807378T PL2318006T3 (pl) | 2008-08-15 | 2009-08-14 | Nowe inhibitory pirolowe reduktazy S-nitrozoglutationu jako środki terapeutyczne |
Country Status (23)
Country | Link |
---|---|
US (7) | US8673961B2 (pl) |
EP (3) | EP2318006B1 (pl) |
JP (4) | JP2012500216A (pl) |
KR (1) | KR20110042364A (pl) |
CN (1) | CN102186478B (pl) |
AU (1) | AU2009281747B2 (pl) |
BR (1) | BRPI0917017B8 (pl) |
CA (1) | CA2734154C (pl) |
CY (2) | CY1117524T1 (pl) |
DK (2) | DK2315591T3 (pl) |
ES (2) | ES2610158T3 (pl) |
HK (2) | HK1156540A1 (pl) |
HR (2) | HRP20160658T1 (pl) |
HU (2) | HUE031580T2 (pl) |
IL (1) | IL211056A (pl) |
LT (1) | LT2318006T (pl) |
PL (2) | PL2318006T3 (pl) |
PT (1) | PT2318006T (pl) |
RU (1) | RU2500668C2 (pl) |
SI (2) | SI2315591T1 (pl) |
SM (2) | SMT201600177B (pl) |
WO (2) | WO2010019910A1 (pl) |
ZA (1) | ZA201100966B (pl) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
WO2010019905A1 (en) | 2008-08-15 | 2010-02-18 | N30 Pharmaceuticals, Llc | Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents |
JP2012500216A (ja) * | 2008-08-15 | 2012-01-05 | エヌサーティー・ファーマシューティカルズ,エルエルシー | 治療薬剤としての、s−ニトロソグルタチオンレダクターゼの新規ピロール阻害剤 |
DK2315590T3 (da) | 2008-08-15 | 2012-11-19 | N30 Pharmaceuticals Inc | Pyrrolinhibitorer af S-nitrosoglutathionreduktase |
EP3354643B1 (en) | 2009-05-01 | 2020-10-28 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
US8586624B2 (en) * | 2009-12-16 | 2013-11-19 | N30 Pharmaceuticals, Inc. | Thiophene inhibitors of S-nitrosoglutathione reductase |
US8946434B2 (en) | 2010-07-16 | 2015-02-03 | N30 Pharmaceuticals, Inc. | Dihydropyridin-2(1H)-one compound as S-nirtosoglutathione reductase inhibitors and neurokinin-3 receptor antagonists |
WO2012039718A1 (en) | 2010-09-24 | 2012-03-29 | N30 Pharmaceuticals, Llc | Novel dihydropyrimidin-2(1h)-one compounds as neurokinin-3 receptor antagonists |
EP2977050A1 (en) | 2010-10-08 | 2016-01-27 | Nivalis Therapeutics, Inc. | Novel substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors |
WO2012083171A1 (en) * | 2010-12-16 | 2012-06-21 | N30 Pharmaceuticals, Llc | Novel substituted bicyclic aromatic compounds as s-nitrosoglutathione reductase inhibitors |
US20140113945A1 (en) * | 2011-07-05 | 2014-04-24 | N30 Pharmaceuticals, Inc. | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents for Liver Toxicity |
US20140135396A1 (en) * | 2011-07-05 | 2014-05-15 | Beth Israel Deaconess Medical Center, Inc. | Treatment of Acetaminophen-Induced Liver Damage by the Administration of Modulators of Nitric Oxide |
AU2013205306B2 (en) | 2012-03-16 | 2015-09-17 | Axikin Pharmaceuticals, Inc. | 3,5-diaminopyrazole kinase inhibitors |
EP3461484B9 (en) | 2013-03-15 | 2021-06-09 | Aerie Pharmaceuticals, Inc. | Dimesylate salts of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl, their combinations with prostaglandins and the use thereof in the treatment of ocular disorders |
NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
JP2016536362A (ja) | 2013-11-08 | 2016-11-24 | バイエル ファーマ アクチエンゲゼルシャフト | 置換されているウラシル類及びそれらの使用 |
EP3066096A1 (de) | 2013-11-08 | 2016-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte uracile als chymase inhibitoren |
JP6364967B2 (ja) * | 2014-05-30 | 2018-08-01 | 東ソー株式会社 | ジチエノベンゾジチオフェンの製造方法 |
MY191736A (en) | 2014-12-23 | 2022-07-13 | Axikin Pharmaceuticals Inc | 3,5-diaminopyrazole kinase inhibitors |
CN104529995B (zh) * | 2014-12-30 | 2016-04-27 | 白银摩尔化工有限责任公司 | 一种空气或纯氧催化氧化溴化氢制备2,3,5-三溴噻吩的方法 |
CN104557656B (zh) * | 2015-01-13 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 含卤苯和二烯金刚烷结构的化合物、其制备方法和用途 |
WO2017044766A1 (en) | 2015-09-10 | 2017-03-16 | Nivalis Therapeutics, Inc. | Solid forms of an s-nitrosoglutathione reductase inhibitor |
CN105218397B (zh) * | 2015-09-25 | 2017-05-10 | 济南大学 | 2‑叠氮甲基‑4‑硝基苯甲酰氯的合成方法 |
JP7086608B2 (ja) | 2016-01-12 | 2022-06-20 | 日本ケミファ株式会社 | 電位依存性t型カルシウムチャネル阻害剤 |
US10537557B2 (en) | 2016-01-27 | 2020-01-21 | Case Western Reserve University | Methods of treating respiratory disorders |
JP6864379B2 (ja) | 2016-03-31 | 2021-04-28 | オンターナル セラピューティック インコーポレイテッドOncternal Therapeutics, Inc. | インドール類似体及びその使用 |
WO2018026812A1 (en) * | 2016-08-01 | 2018-02-08 | Ohio State Innovation Foundation | Antiviral agents |
MX2019002396A (es) | 2016-08-31 | 2019-07-08 | Aerie Pharmaceuticals Inc | Composiciones oftalmicas. |
US9840468B1 (en) | 2016-12-30 | 2017-12-12 | Aerie Pharmaceuticals, Inc. | Methods for the preparation of 6-aminoisoquinoline |
EP3609871A4 (en) | 2017-03-31 | 2021-01-06 | Aerie Pharmaceuticals, Inc. | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS |
JP2020100564A (ja) * | 2017-04-03 | 2020-07-02 | 京都薬品工業株式会社 | リードスルー誘導剤およびその医薬用途 |
JP7249508B2 (ja) * | 2017-04-11 | 2023-03-31 | ジーエスエヌオー セラピューティクス, インコーポレイテッド | カルバゾール化合物及びその使用法 |
EP3634460A4 (en) | 2017-05-08 | 2021-03-03 | Musc Foundation for Research Development | S-NITROSOGLUTATHION (GSNO) AND GSNO-REDUCTASE INHIBITORS FOR USE IN THERAPY |
AU2019337703B2 (en) | 2018-09-14 | 2023-02-02 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
CN110015963A (zh) * | 2019-04-12 | 2019-07-16 | 上海优合生物科技有限公司 | 一种2-氯-6-甲基苯胺的制备方法 |
WO2021026429A1 (en) * | 2019-08-08 | 2021-02-11 | Treventis Corporation | Butyrylcholinesterase compounds and use in diseases of the nervous system |
CN112574193B (zh) * | 2020-12-31 | 2022-05-17 | 南京医科大学 | 一类口服gsnor抑制剂及其药物用途 |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3168527A (en) | 1962-06-14 | 1965-02-02 | Parke Davis & Co | 1-aryl-5-(p-fluorophenyl)-pyrrole-2-propionic acid compounds |
US3168529A (en) * | 1962-06-14 | 1965-02-02 | Parke Davis & Co | 1-(p-lower alkanoylphenyl)-5-arylpyrrole-2-propionic acid compounds |
GB997043A (en) | 1962-06-14 | 1965-06-30 | Parke Davis & Co | Derivatives of 1,5-diarylpyrrole-2-propionic acid |
US3168528A (en) | 1962-06-14 | 1965-02-02 | Parke Davis & Co | 1-(p-nitrophenyl) and 1-(p-cyanophenyl)-5-arylpyrrole-2-propionic acid compounds |
US3168532A (en) * | 1963-06-12 | 1965-02-02 | Parke Davis & Co | 1, 5-diarylpyrrole-2-propionic acid compounds |
US3168531A (en) | 1963-06-12 | 1965-02-02 | Parke Davis & Co | 1-aryl-5-(p-lower alkoxyphenyl)-pyrrole-2-propionic acid compounds |
FR1393615A (fr) | 1964-03-05 | 1965-03-26 | Inst Organiycheskoi Khim Im N | Procédé de préparation de la nu-vinylpyrrolidone |
US3427305A (en) * | 1966-11-01 | 1969-02-11 | Searle & Co | 5 - ((halo/alkoxy)phenyl) - 1 - (p - sulfonamido(phenyl/benzyl)) - 2 - pyrrolepropionic acids |
US3752826A (en) * | 1970-01-26 | 1973-08-14 | Mcneilab Inc | Aroyl substituted pyrroles |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4694018A (en) * | 1985-11-29 | 1987-09-15 | G. D. Serale & Co. | Substituted 1,5-diphenyl-2-pyrrolepropionic acids and derivatives |
US4792568A (en) * | 1986-04-14 | 1988-12-20 | Rorer Pharmaceutical Corporation | Aryl pyrroles as useful antiallergy compounds |
US4826869A (en) | 1988-02-19 | 1989-05-02 | Syntex (U.S.A.) Inc. | N-(lower alkyl)-2-(3'ureidobenzyl)pyrrolidines |
US5189051A (en) | 1990-05-10 | 1993-02-23 | E. I. Du Pont De Nemours And Company | Treatment of glaucoma and ocular hypertension with pyrrole angiotensin-II receptor antagonists |
DE4036706A1 (de) | 1990-11-17 | 1992-05-21 | Hoechst Ag | Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie |
US5187271A (en) | 1991-02-28 | 1993-02-16 | G. D. Searle & Co. | N-substituted (α-imidazolyl-toluyl) pyrrole compounds for treatment of circulatory disorders |
US6008368A (en) * | 1993-04-28 | 1999-12-28 | G. D. Searle & Co. | Pharmaceutical compositions for treatment of circulatory disorders using N-substituted (α-imidazolyl-toluyl) pyrrole aniotensin II antagonists |
US5451597A (en) * | 1993-05-27 | 1995-09-19 | G.D. Searle & Co. | Treatment of circulatory disorders using n-substituted (α-imidazolyl-toluyl) pyrrole angiotensin II antagonists |
US5840751A (en) | 1993-11-19 | 1998-11-24 | Warner-Lambert Company | 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents |
US6057367A (en) | 1996-08-30 | 2000-05-02 | Duke University | Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses |
WO1998020865A2 (en) * | 1996-11-13 | 1998-05-22 | Cold Spring Harbor Laboratory | Therapeutic uses for nitric oxide inhibitors |
CA2273836A1 (en) | 1996-12-10 | 1998-06-18 | G.D. Searle & Co. | Substituted pyrrolyl compounds for the treatment of inflammation |
FR2782720B1 (fr) | 1998-09-01 | 2001-10-12 | Oreal | Utilisation en teinture capillaire de condensats de quinoline-5,8-diones ou de quinoxaline-5,8-diones et de pyrroles, anilines ou indoles substitues |
US6355812B1 (en) * | 1999-06-11 | 2002-03-12 | Orth-Mcneil Pharmaceutical, Inc. | Methods for the synthesis of dioxoalkanoic acid compounds |
US6589978B2 (en) * | 2000-06-30 | 2003-07-08 | Hoffman-La Roche Inc. | 1-sulfonyl pyrrolidine derivatives |
US6359182B1 (en) | 2000-10-26 | 2002-03-19 | Duke University | C-nitroso compounds and use thereof |
US7049308B2 (en) * | 2000-10-26 | 2006-05-23 | Duke University | C-nitroso compounds and use thereof |
US7179791B2 (en) | 2001-01-11 | 2007-02-20 | Duke University | Inhibiting GS-FDH to modulate NO bioactivity |
WO2003000249A1 (fr) | 2001-06-26 | 2003-01-03 | Takeda Chemical Industries, Ltd. | Regulateur de la fonction du recepteur relatif aux retinoides |
GB0119172D0 (en) * | 2001-08-06 | 2001-09-26 | Melacure Therapeutics Ab | Phenyl pyrrole derivatives |
GB0212785D0 (en) | 2002-05-31 | 2002-07-10 | Glaxo Group Ltd | Compounds |
JP2006501217A (ja) | 2002-08-12 | 2006-01-12 | スージェン・インコーポレーテッド | 新規キナーゼ阻害剤としての3−ピロリル−ピリドピラゾールおよび3−ピロリル−インダゾール |
GB0229581D0 (en) | 2002-12-19 | 2003-01-22 | Cyclacel Ltd | Use |
US20060270628A1 (en) | 2003-04-29 | 2006-11-30 | Jagattaran Das | Antiinfective 1,2,3-triazole derivatives, process for their preparation and pharmaceutical compositions containing them |
CA2528155A1 (en) * | 2003-06-04 | 2005-01-06 | Duke University | Compositions and methods for modulating s-nitrosoglutathione reductase |
EP1576954A1 (en) | 2004-03-15 | 2005-09-21 | Yung Shin Pharm. Ind. Co. Ltd. | Preferential inhibition of release of pro-inflammatory cytokines |
MY144903A (en) * | 2004-06-17 | 2011-11-30 | Novartis Ag | Pyrrolopyridine derivatives and their use as crth2 antagonists |
PL1773768T3 (pl) | 2004-07-30 | 2019-03-29 | Exelixis, Inc. | Pochodne pirolu jako środki farmaceutyczne |
CN101006052B (zh) | 2004-07-30 | 2013-11-06 | 埃克塞利希斯股份有限公司 | 作为药用制剂的吡咯衍生物 |
FR2881426B1 (fr) * | 2005-02-03 | 2007-03-30 | Aventis Pharma Sa | Pyrolles et imidazoles substitues, compositions les contenant, procede de frabrication et utilisation |
JP2006290791A (ja) | 2005-04-11 | 2006-10-26 | Astellas Pharma Inc | アゾール置換スルホニルベンゼン誘導体 |
US20080200527A1 (en) | 2005-06-17 | 2008-08-21 | Carex Sa | Cannabinoid Receptor Modulators |
MA28394B1 (fr) | 2005-06-24 | 2007-01-02 | Genelabs Tech Inc | Derives d'heteroaryle pour traitement des virus |
US20090176837A1 (en) | 2005-07-12 | 2009-07-09 | Sony Corporation | Compounds with activity at retinoic acid receptors |
EP2581451B1 (en) * | 2007-12-13 | 2016-03-09 | Indiana University Research and Technology Corporation | Compounds for inhibiting mammalian s-nitrosoglutathione reductase |
US20110104308A1 (en) | 2008-05-09 | 2011-05-05 | Duke University | Treatment For Diseases Relying On Discovery That Thioredoxin Mediates Nitric Oxide |
DK2315590T3 (da) | 2008-08-15 | 2012-11-19 | N30 Pharmaceuticals Inc | Pyrrolinhibitorer af S-nitrosoglutathionreduktase |
WO2010019905A1 (en) | 2008-08-15 | 2010-02-18 | N30 Pharmaceuticals, Llc | Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents |
JP2012500216A (ja) | 2008-08-15 | 2012-01-05 | エヌサーティー・ファーマシューティカルズ,エルエルシー | 治療薬剤としての、s−ニトロソグルタチオンレダクターゼの新規ピロール阻害剤 |
WO2010107476A1 (en) | 2009-03-19 | 2010-09-23 | Duke University | Inhibiting gsnor |
US8586624B2 (en) | 2009-12-16 | 2013-11-19 | N30 Pharmaceuticals, Inc. | Thiophene inhibitors of S-nitrosoglutathione reductase |
US20140113945A1 (en) | 2011-07-05 | 2014-04-24 | N30 Pharmaceuticals, Inc. | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents for Liver Toxicity |
-
2009
- 2009-08-14 JP JP2011523200A patent/JP2012500216A/ja not_active Withdrawn
- 2009-08-14 ES ES09807378.6T patent/ES2610158T3/es active Active
- 2009-08-14 DK DK09807383.6T patent/DK2315591T3/en active
- 2009-08-14 KR KR20117005976A patent/KR20110042364A/ko not_active Application Discontinuation
- 2009-08-14 BR BRPI0917017A patent/BRPI0917017B8/pt not_active IP Right Cessation
- 2009-08-14 HU HUE09807378A patent/HUE031580T2/en unknown
- 2009-08-14 RU RU2011109339/04A patent/RU2500668C2/ru not_active IP Right Cessation
- 2009-08-14 WO PCT/US2009/053931 patent/WO2010019910A1/en active Application Filing
- 2009-08-14 LT LTEP09807378.6T patent/LT2318006T/lt unknown
- 2009-08-14 SI SI200931431A patent/SI2315591T1/sl unknown
- 2009-08-14 DK DK09807378.6T patent/DK2318006T3/en active
- 2009-08-14 HU HUE09807383A patent/HUE027659T2/en unknown
- 2009-08-14 PT PT98073786T patent/PT2318006T/pt unknown
- 2009-08-14 PL PL09807378T patent/PL2318006T3/pl unknown
- 2009-08-14 WO PCT/US2009/053923 patent/WO2010019903A1/en active Application Filing
- 2009-08-14 ES ES09807383.6T patent/ES2572615T3/es active Active
- 2009-08-14 AU AU2009281747A patent/AU2009281747B2/en not_active Ceased
- 2009-08-14 US US13/057,220 patent/US8673961B2/en active Active
- 2009-08-14 CN CN2009801410890A patent/CN102186478B/zh active Active
- 2009-08-14 PL PL09807383.6T patent/PL2315591T3/pl unknown
- 2009-08-14 US US13/057,171 patent/US8691816B2/en not_active Expired - Fee Related
- 2009-08-14 CA CA2734154A patent/CA2734154C/en active Active
- 2009-08-14 EP EP09807378.6A patent/EP2318006B1/en active Active
- 2009-08-14 EP EP16150296.8A patent/EP3069721A1/en not_active Withdrawn
- 2009-08-14 SI SI200931581A patent/SI2318006T1/sl unknown
- 2009-08-14 JP JP2011523205A patent/JP2012500219A/ja active Pending
- 2009-08-14 EP EP09807383.6A patent/EP2315591B1/en active Active
-
2011
- 2011-02-03 IL IL211056A patent/IL211056A/en not_active IP Right Cessation
- 2011-02-07 ZA ZA2011/00966A patent/ZA201100966B/en unknown
- 2011-10-14 HK HK11111007.5A patent/HK1156540A1/zh not_active IP Right Cessation
- 2011-10-18 HK HK11111135.0A patent/HK1156846A1/zh not_active IP Right Cessation
-
2014
- 2014-02-05 US US14/173,377 patent/US8957105B2/en not_active Expired - Fee Related
- 2014-03-11 US US14/204,849 patent/US9138427B2/en not_active Expired - Fee Related
- 2014-10-20 JP JP2014213744A patent/JP5917650B2/ja not_active Expired - Fee Related
- 2014-10-20 JP JP2014213583A patent/JP2015038132A/ja active Pending
-
2015
- 2015-01-15 US US14/598,062 patent/US9180119B2/en not_active Expired - Fee Related
- 2015-10-26 US US14/922,928 patent/US9498466B2/en active Active
-
2016
- 2016-05-18 CY CY20161100428T patent/CY1117524T1/el unknown
- 2016-06-13 HR HRP20160658TT patent/HRP20160658T1/hr unknown
- 2016-06-16 SM SM201600177T patent/SMT201600177B/it unknown
- 2016-11-08 US US15/345,767 patent/US9814700B2/en active Active
-
2017
- 2017-01-09 HR HRP20170019TT patent/HRP20170019T1/hr unknown
- 2017-01-10 CY CY20171100029T patent/CY1118454T1/el unknown
- 2017-01-19 SM SM201700037T patent/SMT201700037B/it unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20160658T1 (hr) | Novi pirolni inhibitori reduktaze s-nitrozoglutationa kao terapeutska sredstva | |
HK1156620A1 (en) | Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents | |
IL250314A0 (en) | Enantiomers of spiro-exindole type substances and their use for the preparation of medical preparations | |
HK1156852A1 (en) | Pyrrole inhibitors of s-nitrosoglutathione reductase s- | |
HK1156306A1 (en) | Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases hif--4- | |
EP2273880A4 (en) | NOVEL COMPOSITIONS FOR THE TREATMENT OF MIGRAINE | |
EP2376091A4 (en) | NEW TARGETS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | |
HRP20171390T1 (hr) | Inhibitor tolerancije na analgetike | |
EP2480086A4 (en) | NOVEL DIHYDROPYRIMIDINE-2 (1H) -ONES COMPOUNDS AS INHIBITORS OF S-NITROSOGLUTATHION REDUCTASE | |
EP2341773A4 (en) | PHARMACEUTICAL COMPOSITIONS FROM ATORVASTATIN | |
EP2512247A4 (en) | NOVEL THIOPHEN INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | |
HRP20130647T1 (en) | Novel composition for treatment of essential thrombocythemia | |
GB2460445B (en) | Treatment of ringworm | |
IL215486A0 (en) | Compositions of cholinesterase inhibitors | |
ZA201006157B (en) | Modified release formulations of hmg coa reductase inhibitors |